Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Nat Commun · 2025-Jul-21 · PMID 40691143
progression-free survival
Fig. 1. Interrogating response heterogeneity via blinded multi-omic analysis of R- versus NR-mesotheliomas. A Upper panel. Kaplan-Meier curve showing investigator-reported progression-free survival for nivolumab and placebo treatment groups in CONFIRM. Lower panel. Kaplan-Meier curve showing overall survival (proportion alive) for nivolumab and placebo treatment groups in CONFIRM. B Chest computerised tomography scan of the chest of a patient who exhibited an extreme response to nivolumab over the course of 6 months. C Archival formalin fixed tumour blocks corresponding to patients who received nivolumab and had either a partial response (R) or progressive disease (no response, NR) as their best outcome, were subjected to next generation sequencing of the whole exome or transcriptome. These tissues were also spatially phenotyped using multiplex-immunofluorescence microscopy. Created in BioRender. Fennell, D. ( https://BioRender.com/sq9aqpm .) D Waterfall plot showing the selection of patients from R- vs NR-groups for blinded multi-omic analysis. E Spider plot showing the relative change from baseline for mesotheliomas in the NR- vs R-subgroups. F Kaplan-Meier plots for investigator reported PFS in the translational research cohorts denoted responder and non-responder respectively. These curves are descriptive only and are not formally comparable. G Kaplan-Meier plot for OS in the translational research cohorts denoted responder and non-responder respectively. These curves are descriptive only and are not formally comparable.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
| Curve | 序号 | X (norm) | Y (norm) | X (real) | Y (real) | X (pixel) | Y (pixel) |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 0.0000 | 0.9481 | -4.0000 | 26 | 58 | |
| 1 | 2 | 0.0573 | 0.9481 | -2.6329 | 35 | 58 | |
| 1 | 3 | 0.0637 | 0.9481 | -2.1772 | 36 | 58 | |
| 1 | 4 | 0.0701 | 0.8961 | -1.7215 | 37 | 62 | |
| 1 | 5 | 0.0764 | 0.8961 | -1.2658 | 38 | 62 | |
| 1 | 6 | 0.0828 | 0.8961 | -0.8101 | 39 | 62 | |
| 1 | 7 | 0.0892 | 0.8961 | -0.3544 | 40 | 62 | |
| 1 | 8 | 0.0955 | 0.8961 | 0.1013 | 41 | 62 | |
| 1 | 9 | 0.1019 | 0.8961 | 0.5570 | 42 | 62 | |
| 1 | 10 | 0.1083 | 0.8961 | 1.0127 | 43 | 62 | |
| 1 | 11 | 0.1146 | 0.8961 | 1.4684 | 44 | 62 | |
| 1 | 12 | 0.1210 | 0.8442 | 1.9241 | 45 | 66 | |
| 1 | 13 | 0.1274 | 0.7273 | 2.3797 | 46 | 75 | |
| 1 | 14 | 0.1338 | 0.7273 | 2.8354 | 47 | 75 | |
| 1 | 15 | 0.1401 | 0.7273 | 3.2911 | 48 | 75 | |
| 1 | 16 | 0.1465 | 0.7273 | 3.7468 | 49 | 75 | |
| 1 | 17 | 0.1529 | 0.7273 | 4.2025 | 50 | 75 | |
| 1 | 18 | 0.1592 | 0.7273 | 4.6582 | 51 | 75 | |
| 1 | 19 | 0.1656 | 0.7273 | 5.1139 | 52 | 75 | |
| 2 | 1 | 0.0000 | 0.8571 | -4.0000 | 26 | 65 | |
| 2 | 2 | 0.0637 | 0.8961 | -2.1772 | 36 | 62 | |
| 2 | 3 | 0.0701 | 0.8961 | -1.7215 | 37 | 62 | |
| 2 | 4 | 0.1783 | 0.6234 | 6.0253 | 54 | 83 | |
| 2 | 5 | 0.1847 | 0.6234 | 6.4810 | 55 | 83 | |
| 2 | 6 | 0.1911 | 0.6234 | 6.9367 | 56 | 83 | |
| 2 | 7 | 0.2484 | 0.4545 | 11.0380 | 65 | 96 | |
| 2 | 8 | 0.2548 | 0.4416 | 11.4937 | 66 | 97 | |
| 2 | 9 | 0.7134 | 0.6364 | 44.3038 | 138 | 82 | |
| 2 | 10 | 0.7197 | 0.6364 | 44.7595 | 139 | 82 | |
| 2 | 11 | 0.7261 | 0.6364 | 45.2152 | 140 | 82 | |
| 2 | 12 | 0.7325 | 0.6364 | 45.6709 | 141 | 82 | |
| 2 | 13 | 0.7389 | 0.6364 | 46.1266 | 142 | 82 | |
| 2 | 14 | 0.7452 | 0.6364 | 46.5823 | 143 | 82 | |
| 2 | 15 | 0.7516 | 0.6364 | 47.0380 | 144 | 82 | |
| 2 | 16 | 0.7580 | 0.6364 | 47.4937 | 145 | 82 |
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T20:48:52+00:00 |